Romanò Massimo
Columbus Clinic Center, Via Buonarroti 48, 20145 Milan, Italy.
Organizing Committee Postgraduate Master in Palliative Care, University of Milan, 20122 Milan, Italy.
J Clin Med. 2025 Jul 17;14(14):5090. doi: 10.3390/jcm14145090.
Heart failure (HF) is a well-known leading cause of mortality, associated with a high symptom burden in advanced stages, frequent hospitalizations, and increasing economic costs. HF is typically classified into three main subgroups, based on left ventricular ejection fraction (LVEF): HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Recently, two additional subgroups have been proposed: HF with improved ejection fraction (HFimpEF) and HF with supernormal ejection fraction (HFsnEF). These five phenotypes exhibit distinct risk factors, clinical presentations, therapeutic responses, and prognosis. However, the LVEF thresholds used to define these subgroups remain a subject of considerable debate, with significant differences in opinions among leading experts. A major criticism concerns the reliability of LVEF in accurately classifying HF subgroups. Due to substantial intra and interobserver variability, determining the appropriate therapy and prognosis can be challenging, particularly in patients with HFmrEF. Additionally, patients classified under HFpEF are often too heterogeneous to be effectively managed as a single group. This narrative review explores these issues, and suggests a possible need for a new approach to HF classification, one that involves revising the LVEF reference values for HF phenotypes and highlighting LVEF trajectories rather than relying on a single measurement. Moreover, in light of the relatively limited therapeutic options for patients with LVEF > 40%, a new, simplified classification may be proposed: HF with reduced EF (LVEF ≤ 40%), HF with below-normal EF (41% ≤ LVEF ≤ 55%), and HF with normal EF (LVEF > 55%). This mindset would better equip clinical cardiologists to manage the diverse spectrum of HF syndromes, always with the patient at the center.
心力衰竭(HF)是一种众所周知的主要死因,在晚期阶段伴有高症状负担、频繁住院以及经济成本增加。根据左心室射血分数(LVEF),HF通常分为三个主要亚组:射血分数降低的HF(HFrEF)、射血分数轻度降低的HF(HFmrEF)和射血分数保留的HF(HFpEF)。最近,又提出了另外两个亚组:射血分数改善的HF(HFimpEF)和射血分数超常的HF(HFsnEF)。这五种表型表现出不同的危险因素、临床表现、治疗反应和预后。然而,用于定义这些亚组的LVEF阈值仍然是一个备受争议的话题,主要专家之间存在重大意见分歧。一个主要批评涉及LVEF在准确分类HF亚组方面的可靠性。由于观察者内和观察者间存在很大差异,确定合适的治疗方法和预后可能具有挑战性,尤其是在HFmrEF患者中。此外,归类为HFpEF的患者往往过于异质,无法作为一个单一群体进行有效管理。本叙述性综述探讨了这些问题,并建议可能需要一种新的HF分类方法,即修订HF表型的LVEF参考值,并强调LVEF轨迹,而不是依赖单一测量。此外,鉴于LVEF>40%的患者治疗选择相对有限,可能会提出一种新的简化分类:EF降低的HF(LVEF≤40%)、EF低于正常的HF(41%≤LVEF≤55%)和EF正常的HF(LVEF>55%)。这种思维方式将更好地使临床心脏病专家能够管理各种HF综合征,始终以患者为中心。